Nasal Spray For Depression: Could A Toad-Venom Psychedelic Help? Scientists Experimental Drug
For people living with depression, finding a treatment that actually works can sometimes take several attempts. Antidepressants may not bring enough relief, while switching medicines or combining treatments can involve m
بقلم Tanya Dutt··16K قراءة
Nasal Spray For Depression: Could A Toad-Venom Psychedelic Help? Scientists Experimental Drug
For people living with depression, finding a treatment that actually works can sometimes take several attempts. Antidepressants may not bring enough relief, while switching medicines or combining treatments can involve more waiting, side effects and uncertainty.
Now, researchers are exploring an unusually different approach: a psychedelic compound related to a substance found in the venom of the Sonoran Desert toad, delivered as a nasal spray. The compound, mebufotenin, also known as 5-MeO-DMT, is being studied for its potential to produce rapid changes in depressive symptoms, including in people whose depression has not improved sufficiently with several antidepressants.
The findings, published in JAMA on October 26, 2026, suggest that a single dose of the psychedelic nasal spray may reduce depressive symptoms while allowing most participants to leave the clinic within about two hours.
Image: Canva
What Is The Toad-Venom Nasal Spray?
The treatment being studied is mebufotenin benzoate, a pharmaceutical formulation of synthetic 5-MeO-DMT. The compound is associated with the Sonoran Desert toad, although the clinical trial did not use material collected from animals.
Mebufotenin acts on serotonin receptors, including 5-HT1A and 5-HT2A receptors, which are involved in mood and perception. Unlike longer-lasting psychedelic experiences associated with substances such as psilocybin or LSD, its acute psychedelic effects are relatively brief.
In simple terms, serotonin is a chemical messenger in the brain that helps regulate mood, emotions and other functions. Mebufotenin interacts with specific receptors that respond to serotonin, potentially triggering changes in how the brain processes emotions and perception. Researchers are studying whether these effects could help ease depressive symptoms, particularly in people who have not responded adequately to conventional antidepressants.
Unlike some psychedelics, whose effects can last for several hours, mebufotenin produces a relatively short-lived psychedelic experience. However, a shorter experience does not necessarily mean the treatment is risk-free or that its benefits will last. Researchers still need to establish how it works, how safe it is and how long any improvement in depression may persist.
The Phase 2b randomised, double-blind trial included 193 adults aged 18 to 75 with moderate to severe major depressive disorder. Participants had not responded adequately to two to five antidepressant treatments during their current depressive episode.
Image: Canva
They received a single intranasal dose of either 8 mg, 12 mg or a very low 0.3 mg comparator, alongside psychological support. At day 29, both active-dose groups showed a greater reduction in depression scores than the low-dose group. The difference for the 12 mg dose was 5.3 points on the Montgomery-Åsberg Depression Rating Scale, while the 8 mg dose showed a 6.2-point difference.
How Does The Nasal Spray Work?
The psychedelic experience itself was short, but the researchers were interested in whether antidepressant effects could last beyond it. Improvements were observed from around two days after dosing and remained greater than the comparator through the follow-up period, which extended to eight weeks.
Most participants were ready to leave the clinic within about two hours once the acute psychedelic effects had subsided. Improvements in depression scores typically began around two days after dosing and continued for at least eight weeks.
Another potentially important finding was how quickly participants recovered from the acute effects. About 85% of those receiving 8 mg and 78% receiving 12 mg were considered ready for discharge within two hours. This could reduce the lengthy monitoring associated with some psychedelic-assisted treatments.
Possible Side Effects
The majority of participants experienced some side effects, but nearly all were mild or moderate and limited to the day of dosing.
Common reactions included headache, nausea and nasal discomfort. One participant had two severe panic attacks during the session. Overall, the safety profile was considered manageable within a supervised clinical setting.
Does This Mean A New Depression Treatment Is Ready?
The findings show potential, not approval or proof that the spray will work for everyone with depression.
An accompanying JAMA commentary raised several limitations, including the fact that the participants had not undergone treatments such as ketamine or electroconvulsive therapy, and people who reported suicidality were excluded. The trial therefore cannot establish how the treatment would perform in people with acute suicidal symptoms or the most difficult-to-treat forms of depression.
The researchers are planning further Phase 3 testing. Until larger studies establish longer-term safety, effectiveness and the need for repeat treatment, mebufotenin nasal spray remains an investigational therapy rather than an available treatment for depression.